Indeed, in tamoxifen-resistant breast cancer, SETD1A silencing dramatically reduces the expression of cell growth genes (e.g., EGFR and MYC) required for the development of tamoxifen resistance, and inhibits cell proliferation by inducing cell cycle arrest [119]. Here, SETD1A is linked to breast cancer.